Further studies are warranted to explore the potential of CXCL6 as a biomarker for early screening and diagnosis of male infertility, evaluate its role in therapeutic development, and assess the clinical feasibility of related drugs such as pioglitazone in improving fertility outcomes of patients struggling with infertility. Here, CXCL6 is linked to male infertility.